A total of 3,512 patients from 19 series underwent SAVR, 806 underwent concurrent coronary artery bypass graft. A total of 5,024 patients from 16 series underwent TAVR, 3,222 (64.1%) used the Edwards-Sapien device (1,840 transubclavian/axilliary and 1,382 transfemoral) and 1,802 used the Medtronic-CoreValve device (1,649 listed access approach: 1,510 transfemoral, 133 trans-axillary and six ascending aortic access by mini-sternotomy).
At baseline, TAVR subjects had statistically significantly greater renal impairment (P<0.001), higher incidence of prior myocardial infarction (P=0.032), respiratory disease (P=0.005) and a higher logistic EuroSCORE (P=0.039).
There were no statistically significant differences between SAVR and TAVR in terms of 30 day mortality (9% versus 8.5%, P=0.31), one year mortality (18.4% versus 22.8%, P=0.65), 30 day stroke (2.4% versus 2.6%, P=0.72), new permanent pacemaker (5.9% versus 12.1%, P=0.055), or dialysis inception (2.4% versus 4.1%, P=0.70).
Apart from some variation in functional status, there were no significant differences at baseline with different Edwards-Sapien and Medtronic-CoreValve designs. The only difference in complications was a greater need for pacemaker insertion with the Medtronic-CoreValve design (24.5% versus 5.9% P<0.0001).